Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.

Cancer · 2022 · PMC9306897 · PMID 35090047

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Among those with positive PD‐L1 expression (TC1/2/3 or IC1/2/3) treated with atezolizumab, an elevated pretreatment LDH level was associated with a nonsignificant trend of worse PFS and OS; this likely reflected the small patient numbers.

also in 5,406 other papers

did not reach statistical significanceno p-value reported

Among those with TC1/2 or IC1/2, elevated pretreatment LDH was similarly associated with worse PFS but did not reach statistical significance (Fig. 6 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.